Supplement for The Effects of Tildrakizumab in the Epigenetic Aging Deviation of Psoriasis: A 52-Week Open-Label Study (Journal of the American Academy of Dermatology, 2026)

Supplement to The Effects of Tildrakizumab in the Epigenetic Aging Deviation of Psoriasis: A 52-Week Open-Label Study, NCT05110313, PI Dr Carlos Wambier, MD, PhD, Rhode Island Hospital, Brown University Health. Figures S1-S6, and Supplementary Tables S1-S2, are within the PDF.